Sutent sunitinib: Phase III discontinued

The open-label, U.S. Phase III SUN 1094 trial was discontinued after an IDMC concluded that Sutent plus paclitaxel would not meet the primary endpoint of superior PFS compared with Avastin bevacizuma...